GW Pharmaceuticals PLC Holding(s) in Company (2854N)
28 January 2016 - 7:47PM
UK Regulatory
TIDMGWP
RNS Number : 2854N
GW Pharmaceuticals PLC
28 January 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or GW PHARMACEUTICALS PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- ------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-----------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------ ---------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------ ---------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------ ---------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------ ---------------------------------
Other (please
specify):
--------------------------------------------------------- ------- ---------------------------------
3. Full name of person(s) The Bank of New York Mellon
subject to the Corporation
notification obligation:
(iii)
----------------------------------------------------------- ----------------------------------------
4. Full name of shareholder(s) The Bank of New York Mellon;
(if different from 3.):(iv) The Dreyfus Corporation; The
Boston Company Asset Management
LLC; BNY Mellon, National
Association; BNY Mellon Capital
Markets, LLC.
----------------------------------------------------------- ----------------------------------------
5. Date of the transaction 26 January 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ----------------------------------------
6. Date on which issuer 27 January 2016
notified:
----------------------------------------------------------- ----------------------------------------
7. Threshold(s) that is/are Crossing above 5%
crossed or
reached: (vi, vii)
----------------------------------------------------------- ----------------------------------------
8. Notified details:
------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- --------------------------------- ----------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------- --------------- ---------------- ------------- --------------------------- --------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ----------- ------------ ------------- -------------- ----------- ------------- -----------
Common Stock 11,862 11,862 11,862 11,862 N/A 0.0045% N/A
GB0030544687
ADR 1,076,351 12,916,212 1,165,618 13,987,416 N/A 5.3270% N/A
--------------- ---------------- ------------- -------------- ----------- ------------- -----------
US36197T1034
------------- ----------- ------------ ----------- ------------ ----------- --------- ---------
B: Qualifying Financial Instruments
------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- ------------------------------- ----------------------------- ----------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- ------------- -------------- --------------- ----------------------------- ------------------------
Nominal Delta
--------------- ------------- -------------- --------------- ----------------------------- ------------- ---------
Total (A+B+C)
------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- --------------------------------------------------------------------
13,999,278 5.33%
-------------------------------------------------- --------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------
The Bank of New York Mellon Corporation is making this
disclosure as the ultimate parent company of: The Bank
of New York Mellon; The Dreyfus Corporation; The Boston
Company Asset Management LLC; BNY Mellon, National Association
and BNY Mellon Capital Markets, LLC.
Proxy Voting:
----------------------------------------------------------------------------
10. Name of the proxy holder: N/A
------------------------------------------------------------ --------------
11. Number of voting rights proxy N/A
holder will cease
to hold:
------------------------------------------------------------ --------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
------------------------------------------------------------ --------------
13. Additional information: N/A
------------------------------------------------------------ --------------
14. Contact name: Andrew Weiser
------------------------------------------------------------ --------------
15. Contact telephone number: 516-338-3752
------------------------------------------------------------ --------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAPFPALKKEEF
(END) Dow Jones Newswires
January 28, 2016 03:47 ET (08:47 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about GW Pharm. (London Stock Exchange): 0 recent articles
More GW Pharm. News Articles